Residual Undifferentiated PSC Detection via Clonal Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The presence of residual undifferentiated pluripotent stem cells (PSCs) in therapeutic compositions poses a risk of tumour formation, particularly in therapies requiring high doses of differentiated PSC-derived cells, necessitating an effective method for detection and quality control.
Innovation Solution
A method involving culturing cells on a substrate coated with laminin-521 and E-cadherin in a medium with a ROCK inhibitor, followed by quantitation of marker expression to detect residual undifferentiated PSCs, comparing it with a reference culture to determine their presence or absence, thereby ensuring the quality and safety of therapeutic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for residual undifferentiated PSCs, then the detection process is simple, but the sensitivity and specificity are insufficient leading to potential false negatives
Solution Approach 1:
The method performs preliminary expansion of residual undifferentiated PSCs in a clonal manner before detection. By culturing cells under conditions that promote clonal expansion of undifferentiated PSCs (using specific substrates like laminin-521 and E-cadherin, and ROCK inhibitors), the method amplifies the presence of residual PSCs before quantitation, thereby increasing detection sensitivity without requiring complex detection equipment
Solution Approach 2:
The invention uses specific culture conditions (laminin-521, E-cadherin, ROCK inhibitors) as intermediaries to selectively expand undifferentiated PSCs. These intermediaries create an environment that favors the proliferation of residual undifferentiated cells while suppressing differentiated cells, enabling more sensitive detection through subsequent marker quantitation
2Reliability
If high doses of differentiated PSC-derived cells are administered therapeutically, then therapeutic efficacy is improved, but the risk of tumour formation from residual undifferentiated PSCs increases
Solution Approach 1:
The method implements a feedback-based quality control system where residual undifferentiated PSCs are detected and quantified before therapeutic administration. The detection results provide feedback on the safety of the cell product, allowing adjustment of purification processes or rejection of batches that exceed acceptable thresholds, thereby preventing tumour formation while enabling high-dose therapy when safe
Solution Approach 2:
The invention converts the potential harm of residual undifferentiated PSCs into a benefit by using their inherent ability to expand clonally under specific conditions. This expansion, which could lead to tumour formation if administered, is instead harnessed as a detection mechanism - the residual PSCs are selectively amplified in culture to enable sensitive detection and quantitation, transforming a safety risk into a quality control advantage
3Measurement precision
If traditional cell culture protocols are used for expansion, then the process is straightforward, but the ability to detect residual undifferentiated PSCs is compromised due to lack of selective expansion
Solution Approach 1:
The method applies local quality by creating a specific microenvironment for cell expansion using particular substrates (laminin-521, E-cadherin) and culture conditions (ROCK inhibitors). This localized optimization of culture conditions selectively promotes the expansion of undifferentiated PSCs while maintaining differentiated cells in a non-proliferating state, enabling sensitive detection without requiring complex manipulation of the entire cell population
Data Source
AI summary
The invention relates to a method for detecting residual, undifferentiated pluripotent stem cells (PSCs) in a culture of cells differentiated from PSCs, the method comprising:culturing the cells on a substrate coated with laminin-521 and E-cadherin in a medium comprising a ROCK inhibitor;quantitating in the cultured cells expression of a marker of residual, undifferentiated PSCs; andcomparing the marker expression in the cultured cells with the marker expression in a reference culture of cells comprising a known proportion of PSCs,wherein lower marker expression in the culture of cells than marker expression in the reference culture of cells indicates absence of residual, undifferentiated PSCs in the cultured cells or presence of residual, undifferentiated PSCs in the cultured cells at a proportion lower than the known proportion of PSCs in the reference culture of cells. The invention also relates to a method for manufacturing a therapeutic composition and a method for treating or preventing a condition in a subject.